Cubist Systematic Strategies, LLC Erasca, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $106,651 - $162,850	-63,863 Reduced 85.99%	10,407 $21,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $124,030 - $184,932	74,270 New	74,270 $158,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $456,497 - $739,726	166,605 Added 72.45%	396,549 $1.19 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $894,482 - $1.97 Million	229,944 New	229,944 $991,000
Q2 2022 Aug 15, 2022	BUY	$4.58 - $8.72 $369,848 - $704,166	80,753 New	80,753 $450,000
Q4 2021 Feb 14, 2022	SELL	$12.51 - $22.75 $579,225 - $1.05 Million	-46,301 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $807,026 - $1.13 Million	46,301 New	46,301 $983,000

133

205M

3.1K

142K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $316M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.